Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity

Among breast cancer patients, those diagnosed with the triple-negative breast cancer (TNBC) subtype have the worst prog-nosis. TNBC does not express estrogen receptor-alpha, progesterone receptor, or the HER2 oncogene; therefore, TNBC lacks targets for molecularly-guided therapies. The concept that...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Autores principales: Bao, Bin, Mitrea, Cristina, Wijesinghe, Priyanga, Marchetti, Luca, Girsch, Emily, Farr, Rebecca L., Boerner, Julie L, Mohammad, Ramzi, Dyson, Greg, Terlecky, Stanley R., Bollig-Fischer, Aliccia
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5345072/
https://ncbi.nlm.nih.gov/pubmed/28281569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep44125
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares